Unmet Need
Melanoma incidence continues to rise sharply, and current therapies remain inadequate for many patient populations, especially those lacking drug‑targetable mutations such as BRAF. A major limitation in melanoma research and drug discovery is the absence of models and targets that reflect the biology of non‑BRAF‑driven melanoma. Recent findings reveal that MRGPRX4, a G protein–coupled receptor previously associated with sensory signaling, is highly overexpressed in human melanoma and acts as a driver of tumor formation, proliferation, invasion, and metastasis. Existing research tools and therapies do not address this pathway, despite strong evidence that modulating MRGPRX4 profoundly impacts melanoma progression. Therefore, there is a critical need for:
- Novel therapeutic strategies that target MRGPRX4;
- Validated platforms that enable MRGPRX4‑specific drug screening;
- Biological systems that allow researchers to model MRGPRX4‑driven melanoma for mechanistic and preclinical studies.
Value Proposition:
- Novel Oncogenic Target: MRGPRX4 represents a previously unrecognized, therapeutically actionable driver of melanoma. Overexpression alone initiates spontaneous, metastatic melanoma in vivo, and loss of MRGPRX4 suppresses proliferation, invasion, and tumor burden.
- Therapeutic Modality Agnostic: The invention enables use of small‑molecule antagonists, antibodies, peptides, or nucleic‑acid‑based inhibitors to suppress MRGPRX4 signaling—creating multiple paths for drug development.
- Broad Clinical Utility: Targeting MRGPRX4 may benefit multiple melanoma types, including cutaneous, uveal, and meningeal melanoma, and may be especially valuable for tumors lacking common driver mutations.
- Diagnostic and Screening Applications: Elevated MRGPRX4 expression provides opportunities for diagnostic assays, prognostic tools, and drug‑screening platforms for evaluating MRGPRX4‑targeting therapeutics.
Technology Description
This invention provides a comprehensive platform centered on MRGPRX4 as a novel oncogenic driver of melanoma, enabling therapeutic, diagnostic, and research applications. The technology includes MRGPRX4 antagonists—such as small molecules, antibodies, peptides, and nucleic‑acid–based inhibitors—to block the receptor’s activity, which has been shown to reduce melanoma cell proliferation, invasion, and tumor growth in human cell lines and xenograft models. Elevated MRGPRX4 expression in human melanoma and its role in driving spontaneous, metastatic melanoma in vivo provide strong mechanistic justification for its use as a drug target, a biomarker for diagnosis, and a screening node for therapeutic discovery.
Stage of Development
· Validated in multiple in vivo models: MRGPRX4 overexpression alone drives rapid, spontaneous, fully penetrant melanoma with metastatic spread.
· Demonstrated functional relevance in human cells: CRISPR knockout of MRGPRX4 significantly reduces proliferation, invasion, and tumor burden in xenograft models.
· Therapeutic concept proven: Multiple classes of antagonists identified and described in the patent.
· Diagnostic and screening applications enabled: Expression analyses using TCGA and preclinical assays confirm MRGPRX4 as a measurable biomarker and target.
Data Availability: Data can be found at the following link, https://doi.org/10.1073/pnas.1903316116
Publication
1. Meixiong, J., Vasavda, C., Snyder, S. H. and Dong, X. (2019c) MRGPRX4 is a G protein-coupled receptor activated by bile acids that may contribute to cholestatic pruritus. Proc. Natl. Acad. Sci. U.S.A. 116, 10525-10530. https://doi.org/10.1073/pnas.1903316116
2. U.S. Patent Application US20240337646
